Enrico Tiacci, MD, discusses updated data of a phase II trial investigating the combination of vemurafenib and rituximab for patients with relapsed/refractory hairy cell leukemia.
Enrico Tiacci, MD
Advertisement
Articles by Enrico Tiacci, MD
Enrico Tiacci, MD, discusses the current treatment options for patients with hairy cell leukemia. Currently, the standard of care for these patients are purine nucleoside analogs, including pentostatin and cladribine.
Enrico Tiacci, MD, discusses safety and efficacy results of a trial evaluating the BRAF inhibitor vemurafenib combined with rituximab in hairy cell leukemia.
Advertisement
Latest Updated Articles
Dr. Tiacci on Vemurafenib/Rituximab Combo in HCLPublished: July 2nd 2019 | Updated:
Dr. Tiacci on Vemurafenib and Rituximab Combo in Hairy Cell LeukemiaPublished: November 28th 2019 | Updated:
Dr. Tiacci on Standard of Care in Hairy Cell Leukemia TreatmentPublished: October 25th 2019 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
4
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
5